Shandong Xinhua Pharmaceutical Co., Ltd. (00719) obtained the drug registration certificate for resorcinol injections

Zhitong Finance App News, Shandong Xinhua Pharmaceutical Co., Ltd. (00719) issued an announcement. Recently, Shandong Xinhua Pharmaceutical Co., Ltd. (hereinafter referred to as “Xinhua Pharmaceutical” or “the Company”) received the “Drug Registration Certificate” for resorcinol injections (hereinafter referred to as “this product”) approved and issued by the State Drug Administration.

In July 2024, Xinhua Pharmaceutical submitted marketing license registration data for drugs produced domestically produced in China to the Drug Evaluation Center (CDE) of the State Drug Administration and was accepted. It obtained the “Drug Registration Certificate” in December 2025. The review concluded that registration was approved.

This product is used to treat acute spasmodic pain caused by digestive system and biliary tract dysfunction; acute spasmodic urethral, bladder, and renal colic; gynecological spasmodic pain.

This product belongs to category B of the “National Catalogue of Drugs for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2025)”. According to relevant statistics, sales of triphenol injections in Chinese public medical institutions in 2024 will be approximately RMB 900 million.